Tango Therapeutics (TNGX) Equity Average (2020 - 2025)
Historic Equity Average for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $147.5 million.
- Tango Therapeutics' Equity Average fell 3813.79% to $147.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $147.5 million, marking a year-over-year decrease of 3813.79%. This contributed to the annual value of $226.3 million for FY2024, which is 994.04% down from last year.
- Latest data reveals that Tango Therapeutics reported Equity Average of $147.5 million as of Q3 2025, which was down 3813.79% from $150.9 million recorded in Q2 2025.
- Tango Therapeutics' Equity Average's 5-year high stood at $355.1 million during Q4 2021, with a 5-year trough of $5.0 million in Q2 2021.
- Its 5-year average for Equity Average is $219.7 million, with a median of $238.4 million in 2024.
- Its Equity Average has fluctuated over the past 5 years, first skyrocketed by 727208.68% in 2021, then crashed by 4108.66% in 2025.
- Quarter analysis of 5 years shows Tango Therapeutics' Equity Average stood at $355.1 million in 2021, then decreased by 26.42% to $261.3 million in 2022, then rose by 1.37% to $264.9 million in 2023, then fell by 19.07% to $214.3 million in 2024, then tumbled by 31.19% to $147.5 million in 2025.
- Its Equity Average was $147.5 million in Q3 2025, compared to $150.9 million in Q2 2025 and $183.1 million in Q1 2025.